Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs labetalol for intraoperative blood loss in rhinoplasty
IRCT20150317021497N7Phase 3Completed
- Sponsor
- Rafsanjan University of Medical Sciences
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in intraoperative bleeding and hypertension (HTN) comparing Dexmedetomidine arm with Labetalol arm (2 arms). Primary endpoints: Intraoperative blood loss volume and Bleeding rate. Started Jul 2022; status: completed.
02
Drugs
dexmedetomidinelabetalol
03
Conditions
intraoperative bleedinghypertension (HTN)
Beyond the preview
Go deeper on IRCT20150317021497N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150317021497N7.